XENON PHARMACEUTICALS INC. Shareholders' Equity
XENON PHARMACEUTICALS INC. (XENE) had Shareholders' Equity of $1.24 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.24B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.34B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $581.76M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $559.51M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.24B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.34B 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $581.76M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $559.51M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $633.98M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $703.96M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $754.90M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $797.81M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $844.05M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $887.70M 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $927.92M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $636.59M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $646.46M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $686.94M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $721.50M 10-K · filed 2026-02-26 | |
| 2022-09-30 | $753.12M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $785.79M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $541.85M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $550.03M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $248.94M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $256.98M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $276.28M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $171.35M 10-K · filed 2024-02-29 | |
| 2020-09-30 | $182.02M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $189.30M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $187.98M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $91.98M 10-K · filed 2023-03-01 | |
| 2019-09-30 | $74.56M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $82.79M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $92.31M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $103.30M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $111.16M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $50.62M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $28.50M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $35.93M 10-K · filed 2020-03-09 | |
| 2017-09-30 | $43.30M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $50.45M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $57.20M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $63.90M 10-K · filed 2019-03-06 | |
| 2016-09-30 | $69.31M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $52.66M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $58.16M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $61.03M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $64.46M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $64.35M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $62.67M 10-Q/A · filed 2015-08-13 | $68.97M 10-Q · filed 2015-05-12 |
| 2014-12-31 | $72.78M 10-K · filed 2018-03-07 | |
| 2014-09-30 | -$67.51M 10-Q · filed 2014-12-15 | |
| 2013-12-31 | -$78.37M 10-K · filed 2017-03-08 | |
| 2012-12-31 | -$89.86M 10-K · filed 2016-03-08 | |
| 2011-12-31 | -$86.32M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |